Clinical application and evaluation of cardiac biomarker CTnI

[Objective]To study the diagnostic value of cardiac troponin I(CTnI) determination on different types of coronary heart diseases.[Methods]By suing the fluorescent immunoassay,CTnI content was detected in 54 patients with different types of coronary heart diseases,including 23 cases of acute myocardial infarction(AMI),13 cases of unstable angina pectoris(UAP) and 18 cases of stable angina pectoris(SAP),and the results were analyzed synthetically.[Results]CTnI contents in patients with different types of coronary heart diseases increased at different degrees,and the positive rate of AMI,UAP and SAP group was 95.7% and 69.2% and 5.6%,respectively.There was no significant difference between SAP group and the control group(P0.05),and the differences between AMI,UAP group and the control group were significant(P0.05).[Conclusion]CTnI is a sensitive and specific cardiac biomarker,and it can be used in the risk classification,outcome and prognosis of patients with early AMI,UAP and acute coronary syndrome(ACS).The increasing CTnI content is related to various risk-factors of coronary heart diseases.CTnI determination can reflect the myocardial injury and necrosis of coronary artery atherosclerosis,which has an important application value in the predictions and diagnosis of dynamic change and cardiovascular events of different types of coronary heart diseases.